It has demonstrated that immune checkpoint inhibitor efficacy is affected by a combination of factors involving tumor genomics, host germline genetics, PD1 ligand 1 (PDL1) levels, and other features of the tumor microenvironment, as well as the gut microbiome (29). Here, CD274 is linked to neoplasm.